BRAF and non-small cell lung carcinoma: This is one of the largest Italian series of advanced NSCLC patients with BRAF mutation, highlighting distinctive features of BRAF V600E and non-V600E mutant NSCLC in terms of survival outcome, therapeutic response, and clinicopathologic correlations.